Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
Mari
Andrea
A
Institute of Biomedical Engineering-CNR, Corso Stati Uniti 4, 35127 Padova, Italy. andrea.mari@isib.cnr.it
Degn
Kristine
K
Brock
Birgitte
B
Rungby
Joergen
J
Ferrannini
Ele
E
Schmitz
Ole
O
D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D010919:Placebos
D001786:Blood Glucose; D007328:Insulin; D010919:Placebos; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1